Efficacy of N-Acetylcysteine (NAC) Against Malondialdehyde (MDA) Levels in Diabetic Cataracts: In vivo Study
DOI:
https://doi.org/10.37275/bsm.v6i8.558Keywords:
Diabetic cataracts, Antioxidants, N-acetylcysteine, MalondialdehydeAbstract
Background: Diabetes mellitus is a systemic condition that affects various organs, including the eyes. N-acetylcysteine (NAC) functions as an antioxidant because it belongs to a thiol group synthesis glutathione. However, the availability of cysteine in the body is only 15%, so cysteine supplementation can help with oxidative stress in diabetic cataracts. That it will prevent the reaction of lipid peroxidase and the formation of PUFA in the lens membrane, which causes damage to lens cells and is characterized by an increase in malondialdehyde. This study aims to determine the comparison of malondialdehyde levels in the lenses of diabetic cataract rats given or without topical NAC.
Methods: 36 rats were divided into the control group (received streptozotocin) and treatment group (received streptozotocin and topical NAC. Intraperitoneal injection of streptozotocin was given 90 mg/kg BW and performed once a week for 3 weeks. GDP examination was performed the next day after the rats fasted for 16 hours from the vein. In the tail, GDP > 110 mg/dl categorized as diabetes. Topical NAC was given 4 times per day for 3 weeks. At the end of the study, the lens was extracted for the measurement of malondialdehyde.
Results: The mean MDA levels in the control group were higher (2.90±0.71nmol/ml) than in the treatment group (2.33±0.38nmol/ml), p<0.05.
Conclusion: NAC was effective in reducing oxidative stress levels in diabetic cataract lenses by lowering MDA levels better than the group that did not receive MDA in vivo.
Authors
- Dining Pratidina1*
- M. Hidayat1
- Andrini Ariesti1
- 1Department of Ophthalmology, Faculty of Medicine, Universitas Andalas, Padang, Indonesia
Corresponding author Dining Pratidina — pratidinadining@gmail.com
Article history
- Submitted
- Accepted
- Published
Downloads
Published
Issue
Section
License
Copyright and licensing
Copyright in each article remains with the author(s). Authors grant Bioscientia Medicina: Journal of Biomedicine and Translational Research a non-exclusive right of first publication and the right to identify itself as the original publisher. No exclusive transfer of copyright is required.
All articles are published under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0): https://creativecommons.org/licenses/by-nc-sa/4.0/. Users may copy, redistribute, remix, transform, and build upon the material for non-commercial purposes, provided appropriate attribution is given, a link to the license is supplied, changes are indicated, and adaptations are distributed under the same license.
The license applies to the article's scholarly content unless a credit line states otherwise. Third-party material may be subject to separate rights. Authors retain patent, trademark, moral, and research-data rights. The copyright year follows the article's publication date.
